PGAM1 and cancer: Elevated levels of PGAM1 are correlated with poor prognosis for NSCLC patients, and knockdown of PGAM1 suppresses aggressive cancer phenotypes as well as mTOR-mediated glycolysis and oncogenesis in NSCLC cells [19, 20].